Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
Charles S VenutoYoninah S CramerSusan L RosenkranzMark SulkowskiDavid L WylesDaniel E CohenJeffrey SchmidtBeverly L Alston-SmithGene D MorsePublished in: British journal of clinical pharmacology (2019)
The majority of participants' plasma raltegravir exposures were lower after initiation of HCV therapy in coinfected adults; however, confidence intervals were wide.